RANI Rani Therapeutics Holdings, Inc.
USHealthcareAs of 2026-07-09 16:00
Why RANI matters now
Rani Therapeutics Holdings, Inc. (RANI) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.70 with +0.75% on the session and $45.6M in market capitalization; recent performance reads 1-month -11.53% and YTD -42.04%.
The latest financial table shown here is Q1 2026, with revenue of $1.7M, net income of $-7.0M, and EPS of $-0.04. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -33.5%.
The latest indexable market news headline is "Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes Imran Talat filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.96
P/S
16.13
EV/EBITDA
-1.36
DCF Value
$0.34
FCF Yield
-33.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.9%
Operating Margin
-1093.0%
Net Margin
-929.1%
ROE
-245.5%
ROA
-56.8%
ROIC
-87.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.7M | $-7.0M | $-0.04 |
| Q4 2025 | $1.5M | $-10.3M | $-0.07 |
| FY 2025 | $1.6M | $-29.7M | $-0.45 |
| Q3 2025 | $0.00 | $-5.4M | $-0.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$15.67
Target (Median)
$10.00
Target Range
$9.00 - $28.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.76
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.